- Home
- CVKD vs MIRA Comparison
CVKD vs MIRA Comparison
Compare CVKD & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | MIRA |
|---|---|---|
| Founded | 2022 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7M | 33.7M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CVKD | MIRA |
|---|---|---|
| Price | $6.93 | $1.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | 79.8K | ★ 244.9K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.42 | $0.73 |
| 52 Week High | $22.90 | $2.45 |
Technical Indicators
Market Signals| Indicator | CVKD | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.73 | 47.92 |
| Support Level | $6.42 | $1.44 |
| Resistance Level | $7.58 | $1.51 |
| Average True Range (ATR) | 0.79 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 19.87 | 14.00 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.